 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Can a New Antibiotic Safely Prevent Travelers' Diarrhea?
17 May 2005 | Volume 142 Issue 10 | Page I-30
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin To Prevent Travelers' Diarrhea." It is in the 17 May 2005 issue of Annals of Internal Medicine (volume 142, pages 805-812). The authors are H.L. DuPont, Z.-D. Jiang, P.C. Okhuysen, C.D. Ericsson, F. Javier de la Cabada, S. Ke, M.W. DuPont, and F. Martinez-Sandoval.
What is the problem and what is known about it so far?
Travelers to developing countries often develop diarrhea, which is usually caused by consuming food or water contaminated with bacteria. Daily antibiotics can prevent travelers' diarrhea but have many adverse effects, such as making bacteria in the body more resistant to antibiotics. Therefore, the risk of taking daily antibiotics to prevent travelers' diarrhea is usually considered greater than the benefit. Rifaximin, an antibiotic used in other countries to treat diarrhea, recently became available in the United States. Rifaximin is an effective treatment for travelers' diarrhea once it has developed and might also be useful for preventing travelers' diarrhea.
Why did the researchers do this particular study?
To see if rifaximin is safe and effective when taken to prevent travelers' diarrhea.
Who was studied?
210 students from the United States who were attending classes in Guadalajara, Mexico. The students were at risk for travelers' diarrhea because they lived with local families. All were older than age 18 years and were generally healthy.
How was the study done?
The researchers randomly assigned the students to take rifaximin or placebo for 2 weeks after their arrival in Mexico. They asked the students to keep a diary of symptoms and then compared how many people developed diarrhea or adverse drug effects. They also checked to see if the antibiotic led to changes in the kinds of normal bacteria that live in the gut and in the antibiotic resistance of those bacteria.
What did the researchers find?
Approximately 15% of students who took rifaximin and more than 50% of the students who took placebo developed diarrhea. Side effects were similar in all groups. No important changes in the type of gut bacteria or the antibiotic resistance of those bacteria were detected in students taking the antibiotic.
What are the limitations of the study?
The study findings may not apply to areas where travelers' diarrhea is caused by bacteria different from those in Mexico. They also do not apply to travelers' diarrhea caused by viruses, against which antibiotics have no effect. The study duration was 4 to 5 weeks. Findings might differ over longer time periods.
What are the implications of the study?
Rifaximin appears to prevent travelers' diarrhea in Mexico when taken daily for 2 weeks. It is not a substitute for careful selection and preparation of food and water to avoid infection.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  K. A. Grimes, J. A. Mohamed, H. L. DuPont, R. S. Padda, Z.-D. Jiang, J. Flores, J. Belkind-Gerson, F. G. Martinez-Sandoval, and P. C. Okhuysen PCR-Based Assay Using Occult Blood Detection Cards for Detection of Diarrheagenic Escherichia coli in Specimens from U.S. Travelers to Mexico with Acute Diarrhea J. Clin. Microbiol., July 1, 2008; 46(7): 2227 - 2230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kokkotou, A. C. Moss, A. Michos, D. Espinoza, J. W. Cloud, N. Mustafa, M. O'Brien, C. Pothoulakis, and C. P. Kelly Comparative Efficacies of Rifaximin and Vancomycin for Treatment of Clostridium difficile-Associated Diarrhea and Prevention of Disease Recurrence in Hamsters Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1121 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Lauritano, A. L. Bilotta, M. Gabrielli, E. Scarpellini, A. Lupascu, A. Laginestra, M. Novi, S. Sottili, M. Serricchio, G. Cammarota, et al. Association between Hypothyroidism and Small Intestinal Bacterial Overgrowth J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4180 - 4184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Clarke, S. Hopewell, and I. Chalmers Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report J R Soc Med, April 1, 2007; 100(4): 187 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. CABADA, F. MALDONADO, W. QUISPE, K. MOZO, E. SERRANO, E. GONZALEZ, C. SEAS, K. VERDONCK, J. I. ECHEVARRIA, H. L. DUPONT, et al. RISK FACTORS ASSOCIATED WITH DIARRHEA AMONG INTERNATIONAL VISITORS TO CUZCO, PERU Am J Trop Med Hyg, November 1, 2006; 75(5): 968 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pimentel, S. Park, J. Mirocha, S. V. Kane, and Y. Kong The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med, October 17, 2006; 145(8): 557 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Greenberger and P. Sharma Update in Gastroenterology and Hepatology Ann Intern Med, August 15, 2006; 145(4): 294 - 298. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Diemert Prevention and Self-Treatment of Traveler's Diarrhea Clin. Microbiol. Rev., July 1, 2006; 19(3): 583 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. TAYLOR, A. L. BOURGEOIS, C. D. ERICSSON, R. STEFFEN, Z.-D. JIANG, J. HALPERN, R. HAAKE, H. L. DUPONT, and THE RIFAXIMIN STUDY GROUP A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF RIFAXIMIN COMPARED WITH PLACEBO AND WITH CIPROFLOXACIN IN THE TREATMENT OF TRAVELERS' DIARRHEA Am J Trop Med Hyg, June 1, 2006; 74(6): 1060 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. RIDDLE, J. W. SANDERS, S. D. PUTNAM, and D. R. TRIBBLE Incidence, etiology, and impact of diarrhea among long-term travelers (us military and similar populations): a systematic review. Am J Trop Med Hyg, May 1, 2006; 74(5): 891 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ko, C. Garcia, Z.-D. Jiang, P. C. Okhuysen, J. Belkind-Gerson, R. I. Glass, and H. L. DuPont Noroviruses as a Cause of Traveler's Diarrhea among Students from the United States Visiting Mexico J. Clin. Microbiol., December 1, 2005; 43(12): 6126 - 6129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Journal Watch Arch. Dis. Child., November 1, 2005; 90(11): 1200 - 1201. [Full Text] [PDF]
|
|
|
|
|
|
Correction: A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin To Prevent Travelers' Diarrhea Ann Intern Med, August 2, 2005; 143(3): 239 - 239. [Full Text] [PDF]
|
|
|
|
 |
|
 Travelers' Diarrhea: A New Approach Journal Watch Pediatrics and Adolescent Medicine, July 8, 2005; 2005(708): 6 - 6. [Full Text]
|
|
|
|
 |
|
 Prophylaxis of Traveler's Diarrhea Using Rifaximin Journal Watch Infectious Diseases, June 24, 2005; 2005(624): 3 - 3. [Full Text]
|
|
|
|
 |
|
 Rifaximin Is an Effective Prophylaxis for Travelers' Diarrhea Journal Watch Gastroenterology, June 14, 2005; 2005(614): 5 - 5. [Full Text]
|
|
|
|
 |
|
 Rifaximin Can Prevent Travelers' Diarrhea Journal Watch (General), June 14, 2005; 2005(614): 4 - 4. [Full Text]
|
|
|
|
 |
|
 A. Tonks Short cuts: What's new in the other general journals BMJ, May 28, 2005; 330(7502): 1231 - 1232. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Gorbach How To Hit the Runs for Fifty Million Travelers at Risk Ann Intern Med, May 17, 2005; 142(10): 861 - 862. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
